{
    "nctId": "NCT00027885",
    "briefTitle": "Phase II Bevacizumab + Tax In Advanced Breast Cancer",
    "officialTitle": "A Randomized Phase II Study of Bevacizumab in Combination With Docetaxel in Locally Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 49,
    "primaryOutcomeMeasure": "To evaluate the ability of bevacizumab and docetaxel to reduce microvessel density and induce apoptosis of endothelial and tumor cells.",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the breast\n\n  * Stage IIIA or IIIB\n  * Stage IV if patient has clinical evidence of locally advanced breast cancer only\n  * Inoperable disease\n* Prior carcinoma in situ of the breast or bilateral breast cancer is allowed\n* No CNS metastases\n* Hormone receptor status:\n\n  * Estrogen and progesterone receptor status known\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 18 and over\n\nSex:\n\n* Female or male\n\nMenopausal status:\n\n* Not specified\n\nPerformance status:\n\n* ECOG 0-2 OR\n* Karnofsky 60-100%\n\nLife expectancy:\n\n* More than 6 months\n\nHematopoietic:\n\n* WBC at least 3,000/mm\\^3\n* Absolute neutrophil count at least 1,500/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n\nHepatic:\n\n* Bilirubin normal (no greater than 2 times upper limit of normal \\[ULN\\] in patients with an inherited disorder)\n* AST/ALT no greater than 2.5 times ULN\n* INR and PTT normal\n\nRenal:\n\n* Creatinine normal OR\n* Creatinine clearance at least 60 mL/min\n* No proteinuria or clinically significant renal impairment\n\nCardiovascular:\n\n* LVEF at least 45% by echocardiogram or MUGA scan\n* No New York Heart Association class III or IV heart disease\n* No symptomatic congestive heart failure\n* No unstable angina pectoris\n* No cardiac arrhythmia\n* No inadequately controlled hypertension\n* No history of deep vein thrombosis or other thromboses\n* No clinically significant peripheral artery disease\n* No arterial thromboembolic event within the past 6 months including the following:\n\n  * Transient ischemic attack\n  * Cerebrovascular accident\n  * Myocardial infarction\n\nOther:\n\n* No other prior or concurrent malignancy within the past 10 years except inactive nonmelanoma skin cancer or carcinoma in situ of the cervix\n* No other uncontrolled concurrent illness\n* No ongoing or active infection\n* No non-healing wounds\n* No psychiatric illness or social situation that would preclude study participation\n* No prior allergic reaction to compounds of similar chemical or biological composition to bevacizumab, docetaxel, polysorbate 80 (Tween) formulations, or other agents used in this study\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective barrier contraception\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* No concurrent cytokines during docetaxel/bevacizumab administration\n\n  * Concurrent cytokines during doxorubicin/cyclophosphamide administration allowed at the discretion of the treating physician\n\nChemotherapy:\n\n* No prior chemotherapy\n\nEndocrine therapy:\n\n* Prior hormonal therapy (e.g., tamoxifen) allowed\n\nRadiotherapy:\n\n* Prior radiotherapy to affected breast allowed\n\nSurgery:\n\n* More than 28 days since prior major surgery\n\nOther:\n\n* At least 10 days since prior thrombolytic agents\n* At least 10 days since prior full-dose oral or parenteral anticoagulants except to maintain patency of permanent indwelling IV catheters\n* Concurrent warfarin allowed provided INR is less than 1.5\n* Concurrent bisphosphonates allowed for osseous metastases provided they are not initiated on day 1 of cycle 1\n* No concurrent combination antiretroviral therapy for HIV-positive patients\n* No concurrent full-dose oral or parenteral anticoagulants except to maintain patency of permanent indwelling IV catheters\n* No concurrent thrombolytic agents\n* No other concurrent anticancer agents or therapies\n* No other concurrent investigational agents",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}